Concepedia

Long‐term efficacy and safety of stapokibart for moderate‐to‐severe atopic dermatitis: 52‐week results from a phase 3 trial

Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Jingyi Li, Qingchun Diao, Qing Sun, Xiaohong Zhu,

Allergy · 2024 · 18 citations · 25 references

DOIFull text

Open access

Abstract

Long-term treatment with stapokibart demonstrated a sustained efficacy and favorable safety profile in adults with moderate-to-severe AD.

References

25

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham et al. · The Lancet · 2017 · 1.2K citations · Full text

, , +8

Guidelines of care for the management of atopic dermatitis

Lawrence F. Eichenfield, Wynnis L. Tom, Timothy G. Berger et al. · Journal of the American Academy of Dermatology · 2014 · 1.2K citations · Full text

, , +3

Guidelines of care for the management of atopic dermatitis

Robert Sidbury, Dawn Marie R. Davis, David E. Cohen et al. · Journal of the American Academy of Dermatology · 2014 · 851 citations · Full text

, , +3

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 553 citations · Full text

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 502 citations

, , +9